ArticleJournal of nanobiotechnology2025
Atractylodes macrocephala-derived extracellular vesicles-like particles enhance the recovery of ulcerative colitis by remodeling intestinal microecological balance.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Extracellular Vesicles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- Engineering Plant-Derived Exosome-like Nanoparticles as Bioinspired Nanocarriers: From Physicochemical Properties to Tumor Delivery Performance.Biomedicines · 2026Review
- Mechanisms of Gut Microbiota-Derived Metabolites in Treating Hyperuricemia: Natural Products as Interventions.Molecules (Basel, Switzerland) · 2026Review
- Advances in Nano-Drug Delivery Systems for Chronic Autoimmune Diseases: A Focus on Diabetes Mellitus, Inflammatory Bowel Disease, and Rheumatoid Arthritis.Molecules (Basel, Switzerland) · 2026Review
- Comparative Analysis of Extracellular Vesicle-Like Particles From Different ProcessingFood science & nutrition · 2026Article
- Exosomal nanovesicles derived from Atractylodes macrocephala delivering exogenous miRNA-146a-5p for treatment of sepsis-induced acute kidney injury.Journal of nanobiotechnology · 2026Article
- Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment.Oncology letters · 2026Article
- Biogenesis, preparation, characterization, therapeutic mechanisms and safety evaluation of plant-derived exosome-like nanovesicles in the treatment of ulcerative colitis.Journal of nanobiotechnology · 2026Review
- Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy.Antioxidants (Basel, Switzerland) · 2026Review
- Plant-Derived Extracellular-Vesicle-Like Particles: Immune Regulation and Disease Therapy.Research (Washington, D.C.) · 2026Review
- Study on the mechanism of action of Kangfuxin liquid in alleviating DSS-induced ulcerative colitis in mice.Frontiers in pharmacology · 2026Article
- Dosing of plant-derived extracellular vesicles in traditional Chinese medicine: current status, root causes, and standardization pathways.Frontiers in pharmacology · 2026Article
- Combined therapy with vitamin D, mesalazine, and microecological preparations improves clinical outcome in ulcerative colitis.American journal of translational research · 2026Article
- Harnessing plant-derived extracellular vesicles in advanced biomaterials: from structural scaffolds to responsive systems for next-generation wound therapeutics.Burns & trauma · 2026Review
- Oral plant-derived exosome-like nanovesicles: a new therapeutic perspective for intestinal diseases.Frontiers in pharmacology · 2026Review
- Therapeutic Effect of Membrane Vesicle Drug Delivery Systems in Inflammatory Bowel Disease.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Current treatment of ulcerative colitis (UC) remains challenging, with the mainstay of therapy being 5-aminosalicylic acid-based drugs, which have limited and inconsistent results. Atractylodes macrocephala (AM) is a traditional Chinese medicine commonly used in the clinical treatment of various inflammatory diseases. Herein, we demonstrate that AM-derived extracellular vesicle-like particles (AMEVLP) can effectively modulate the gut microbiota, thereby significantly improving the treatment efficiency of UC. This is achieved by enhancing the alpha diversity of the gut microbiota and re-establishing beneficial types, which in turn alter tryptophan metabolism, leading to an increase in indole derivatives within the gut. This process also protects the gut barrier and exerts anti-inflammatory effects. The mechanism behind these anti-inflammatory effects is closely associated with the Th17 cell differentiation signaling pathway. It is believed that the AMEVLP enable them to efficiently remodel gut microbiota, providing an avenue for the treatment of various inflammatory diseases. Significantly, preliminary clinical trials have shown that AMEVLP can substantially slow the progression of the disease in UC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.